Klinger, C L. Group B streptococcal vaccines: a review. Vaccines in practice 2008; 1.2: 4

Vaccines in practice

Reference list

Klinger, C L. Group B streptococcal vaccines: a review. Vaccines in practice 2008; 1.2: 4–5.

1. Weisner AM, Johnson AP, Lamagni TL et al. Characterization of group B streptococci recovered from infants with invasive disease in England and Wales. Clin Infect Dis 2004; 38: 1203–1208.

2. Regan JA, Klebanoff MA, Nugent RP et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996. 174: 1354–1360.

3. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis, 2005; 41: 839–847.

4. Anthony BF, Okada DM, Hobel CJ. Epidemiology of Group B Streptococcus: longitudinal observations during pregnancy. J Infect Dis 1978; 137: 524–530.

5. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973; 83: 919–925.

6. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51: 1–22.

7. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for the prevention of group-B-streptococcal disease on the incidence and ecology of early onset neonatal sepsis. The Lancet Infect Dis 2003; 3: 201–213.

8. Jones N, Oliver K, Jones Y, Haines A, Crook D. Carriage of group B streptococcus in pregnant women from Oxford, UK. J Clin Pathol 2006; 59: 363–366.

9. Baker CJ, Rench MA, Edwards MS et al. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988; 319: 1180–1185.

10. Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 2004; 190: 558–564.

11. Baker CJ, Paoletti LC, Rench MA et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis 2000; 182: 1129–1138.

12. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142–150.

13. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21: 3468–3472.

14. Baker CJ, Paoletti LC, Rench MA et al. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis, 2004; 189: 1103–1112.

15. Baker CJ, Rench MA, Fernandez M et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188: 66–73.

16. Luan SL, Granulund M, Sellin M et al. Multilocus sequence typing of Swedish invasive group B streptococcus isolates indicates a neonatally associated genetic lineage and capsule switching. J Clin Microbiol, 2005; 43: 3727–3733.

17. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalctiae, a pathogen causing invasive neonatal disease. Mol Microbiology 2002; 45: 1499–1513.

18. Madoff LC, Michel JL, Gong EW, Rodewald AK. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun 1992; 60: 4989–4994.

19. Larsson C, Stålhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect immun 1996; 64: 3518–3523.

20. Brodeur BR, Boyer M, Charlebois I et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect immun 2000; 68: 5610–5618.

21. Cheng Q, Carlson B, Pillai S et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect immun 2001; 69: 2302–2308.

22. Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B streptococcus beta C protein and a variant with the deletion of its immunoglobulin A binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 2007; 75: 3455–3461.

23. Yung HH, Mascuch SJ, Madoff LC, Paoletti LC. Recombinant group B Streptococcus alpha- like protein 3 is an effective immunogen and carrier protein. Clin Vaccine Immunol 2008; 15: 1035–1041.

24. Snape MD, Kelly DF, Salt P et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43: 1387–1394.

Published by Hayward Medical Communications